The G1691A Mutation of the Factor V Gene (Factor V Leiden) and the G20210A Mutation of the Prothrombin Gene as Risk Factors in Thrombotic Microangiopathies

Abstract

Factor V Leiden (FVL) mutation and prothrombin G20210A mutation are common hereditary risk factors for venous thrombosis. In the current study, 40 patients (mean age ± standard deviation, 35 ± 11 years) and 764 healthy control subjects (mean age ± standard deviation, 37 ± 14 years) were enrolled to assess the potential role of these mutations in the manifestation of thrombotic microangiopathies. Compared with controls, neither the heterozygous FVL mutation (7.5% vs 8.5%; P = 1) nor the heterozygous prothrombin mutation (2.5% vs 2.8%; P = 1) was more prevalent in the patients. The findings do not support a significant role of FVL and prothrombin mutations as risk factors for the manifestation of thrombotic microangiopathies. Thus, screening for these mutations does not allow the identification of individuals at increased risk for these rare thrombotic disorders.

Keywords

thrombotic microangiopathies factor V Leiden mutation prothrombin mutation

References

Seligsohn U. , Lubetsky A. Genetic susceptibility to venous thrombosis . N Engl J Med. 2001;344:1222-1231.

Aznar J. , Mira Y. , Vaya A. , et al. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb Haemost. 2004;91: 1031-1034.

Lalouschek W. , Schillinger M. , Hsieh K. , et al. Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke. 2005:36:1405-1409.

Kaykcoglu M. , Hasedmir C. , Eroglu Z. , et al. Homozygous factor V Leiden mutation in two siblings presenting with acute myocardial infarction: a rare cause of myocardial infarction in the young. Blood Coagul Fibrinolysis . 2005;16:281-286.

Segev A. , Ellis MH , Segev F. , et al. High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors. Int J Cardiol . 2005;98:421-424.

Moake JL Thrombotic microangiopathies. N Engl J Med. 2002;347:589-600.

Franchini M. , Zaffanelli M. , Veneri D. Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome . Thromb Res. 2006;118:177-184.

George JN , Vesely SK , Terrell DR The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol. 2004;41:60-67.

Zotz RB , Maruhn-Debowski B. , Scharf RE Mutation in the gene coding for coagulation factor V and resistance to activated protein C: detection of the genetic mutation by oligonucleotide ligation assay using a semi-automated system. Thromb Haemost. 1996;76:53-55.

10.

Lay MJ , Wittwer CT Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR . Clin Chem. 1997;43:2262-2267.

11.

Von Ahsen N. , Schutz E. , Armstrong VW , Oellerich M. Rapid detection of prothrombotic mutations of prothrombin (G20210A), factor V (G1691A), and methylentetrahydrofolate reductase (C677T) by real-time fluorescence OCR with the LightCycler. Clin Chem. 1999;45:694-696.

12.

Krieg S. , Studt JD , Sulzer I. , Lammle B. , Hovinga JA Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency? Thromb Haemost. 2005;94:1186-1189.

13.

Raife T. , Lentz S. , Atkinson B. , Vesely S. , Hessner M. Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood. 2002;99:437-442.